Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Recent Advances in Inhalation Therapy
share announcement

Recent Advances in Inhalation Therapy

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 20 February 2025 | Viewed by 4619

Special Issue Editors

Dr. Luca Casula

E-Mail Website
Guest Editor
Unit of Drug Sciences, Department of Life and Environmental Sciences, University of Cagliari, 09124 Cagliari, Italy
Interests: nanosuspensions; electrospun nanofibers; cubosomes; phospholipid vesicles; pulmonary delivery; brain delivery
Special Issues, Collections and Topics in MDPI journals
Dr. Francesco Lai

E-Mail Website
Guest Editor
Department of Life and Environmental Sciences, University of Cagliari, 09124 Cagliari, Italy
Interests: nanocrystals; transdermal delivery; brain delivery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, the pharmaceutical technology field has witnessed remarkable improvements, revolutionizing the approaches to and administration of drugs for respiratory conditions. The benefits of inhalation therapy include non-invasiveness, rapid onset, reduced local metabolic enzymes and localized drug delivery. The goal of this Special Issue is to collect the most recent advancements and cutting-edge discoveries in the field of inhalation therapy. These include, but are not limited to, the development of specific formulations for delivery to the lungs, investigations on the pulmonary drug delivery process and pulmonary deposition in vitro, in silico and in vivo, and the creation of innovative inhaler devices. Moreover, studies focused on advanced delivery strategies for drugs and biopharmaceuticals, such as the use of nanotechnology (nanosuspensions, liposomes and others nanocarriers) and inhalable microparticles, are highly welcomed.

This Special Issue will include original research and thematic reviews on any aspects related to the above-mentioned topics. Expert opinions on clinical translation and speculative hypotheses on debated topics are also invited.

Dr. Luca Casula
Dr. Francesco Lai
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inhalation therapy
  • pulmonary delivery
  • aerosols
  • dry powder inhalation
  • inhalable micro and nanoparticles
  • pulmonary deposition

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

30 pages, 5246 KiB  
Review
Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery
by Sara E. Maloney Norcross, Leanna P. K. Levin, Anthony J. Hickey and David B. Hill
Pharmaceuticals 2024, 17(12), 1628; https://doi.org/10.3390/ph17121628 - 4 Dec 2024
Viewed by 502
Abstract
Natural and synthetic biopolymers are gaining popularity in the development of inhaled drug formulations. Their highly tunable properties and ability to sustain drug release allow for the incorporation of attributes not achieved in dry powder inhaler formulations composed only of micronized drugs, standard [...] Read more.
Natural and synthetic biopolymers are gaining popularity in the development of inhaled drug formulations. Their highly tunable properties and ability to sustain drug release allow for the incorporation of attributes not achieved in dry powder inhaler formulations composed only of micronized drugs, standard excipients, and/or carriers. There are multiple physiological barriers to the penetration of inhaled drugs to the epithelial surface, such as the periciliary layer mucus mesh, pulmonary macrophages, and inflammation and mucus compositional changes resulting from respiratory diseases. Biopolymers may facilitate transport to the epithelial surface despite such barriers. A variety of categories of biopolymers have been assessed for their potential in inhaled drug formulations throughout the research literature, ranging from natural biopolymers (e.g., chitosan, alginate, hyaluronic acid) to those synthesized in a laboratory setting (e.g., polycaprolactone, poly(lactic-co-glycolic acid)) with varying structures and compositions. To date, no biopolymers have been approved as a commercial dry powder inhaler product. However, advances may be possible in the treatment of respiratory diseases and infections upon further investigation and evaluation. Herein, this review will provide a thorough foundation of reported research utilizing biopolymers in dry powder inhaler formulations. Furthermore, insight and considerations for the future development of dry powder formulations will be proposed. Full article
(This article belongs to the Special Issue Recent Advances in Inhalation Therapy)
►▼ Show Figures

Graphical abstract

29 pages, 2155 KiB  
Review
Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine
by Elena Cojocaru, Ovidiu Rusalim Petriș and Cristian Cojocaru
Pharmaceuticals 2024, 17(8), 1059; https://doi.org/10.3390/ph17081059 - 12 Aug 2024
Viewed by 3486
Abstract
Inhaled nanoparticle (NP) therapy poses intricate challenges in clinical and pharmacodynamic realms. Recent strides have revolutionized NP technology by enabling the incorporation of diverse molecules, thus circumventing systemic clearance mechanisms and enhancing drug effectiveness while mitigating systemic side effects. Despite the established success [...] Read more.
Inhaled nanoparticle (NP) therapy poses intricate challenges in clinical and pharmacodynamic realms. Recent strides have revolutionized NP technology by enabling the incorporation of diverse molecules, thus circumventing systemic clearance mechanisms and enhancing drug effectiveness while mitigating systemic side effects. Despite the established success of systemic NP delivery in oncology and other disciplines, the exploration of inhaled NP therapies remains relatively nascent. NPs loaded with bronchodilators or anti-inflammatory agents exhibit promising potential for precise distribution throughout the bronchial tree, offering targeted treatment for respiratory diseases. This article conducts a comprehensive review of NP applications in respiratory medicine, highlighting their merits, ranging from heightened stability to exacting lung-specific delivery. It also explores cutting-edge technologies optimizing NP-loaded aerosol systems, complemented by insights gleaned from clinical trials. Furthermore, the review examines the current challenges and future prospects in NP-based therapies. By synthesizing current data and perspectives, the article underscores the transformative promise of NP-mediated drug delivery in addressing chronic conditions such as chronic obstructive pulmonary disease, a pressing global health concern ranked third in mortality rates. This overview illuminates the evolving landscape of NP inhalation therapies, presenting optimistic avenues for advancing respiratory medicine and improving patient outcomes. Full article
(This article belongs to the Special Issue Recent Advances in Inhalation Therapy)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop